Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
Neutralizing monoclonal antibodies (mAbs) for pre- and post-exposure prophylaxis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are largely used to prevent the progression of the disease by blocking viral attachment, host cell entry, and infectivity. Sotrovimab, like other available...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/1/102 |
| _version_ | 1797436487311032320 |
|---|---|
| author | Gaetano Cicchitto Lorena Cardillo Davide Sequino Paola Sabatini Luisa Adamo Rosita Marchitiello Maurizio Viscardi Loredana Cozzolino Antonietta Cavallera Marialuisa Bocchino Alessandro Sanduzzi Zamparelli Francesco Ferrigno Esterina de Carlo Claudio de Martinis Giovanna Fusco |
| author_facet | Gaetano Cicchitto Lorena Cardillo Davide Sequino Paola Sabatini Luisa Adamo Rosita Marchitiello Maurizio Viscardi Loredana Cozzolino Antonietta Cavallera Marialuisa Bocchino Alessandro Sanduzzi Zamparelli Francesco Ferrigno Esterina de Carlo Claudio de Martinis Giovanna Fusco |
| author_sort | Gaetano Cicchitto |
| collection | DOAJ |
| description | Neutralizing monoclonal antibodies (mAbs) for pre- and post-exposure prophylaxis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are largely used to prevent the progression of the disease by blocking viral attachment, host cell entry, and infectivity. Sotrovimab, like other available mAbs, has been developed against the receptor binding Domain of the <i>Spike</i> (S) glycoprotein of the virus. Nevertheless, the latest Omicron variant has shown marked mutations within the S gene, thus opening the question of the efficacy of these neutralizing molecules towards this novel variant. In the present observational study, we describe the effects of Sotrovimab in the treatment of 15 fully vaccinated patients, infected by SARS-CoV-2 Omicron sub-variants, who were selected on the basis of factors widely considered to affect a worse prognosis: immune suppression (<i>n</i> = 12) and/or chronic kidney disease (<i>n</i> = 5) with evidence of interstitial pneumonia in nine patients. The effectiveness of Sotrovimab in the treatment of severe cases of COVID-19 was demonstrated by the regression of symptoms (mean 5.7 days), no need of hospitalisation, improvement of general health conditions and viral clearance within 30 days in all patients. In conclusion, although loss or reduction of mAbs neutralizing activity against the Omicron variant have been described, Sotrovimab has clinically proven to be a safe and useful treatment for patients with high risk of progression to severe COVID-19 infected by Omicron sub-variants. |
| first_indexed | 2024-03-09T11:02:17Z |
| format | Article |
| id | doaj.art-86b5286ecdaf4dd8947bed8801be7868 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T11:02:17Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-86b5286ecdaf4dd8947bed8801be78682023-12-01T01:10:00ZengMDPI AGViruses1999-49152022-12-0115110210.3390/v15010102Effectiveness of Sotrovimab in the Omicron Storm Time: A Case SeriesGaetano Cicchitto0Lorena Cardillo1Davide Sequino2Paola Sabatini3Luisa Adamo4Rosita Marchitiello5Maurizio Viscardi6Loredana Cozzolino7Antonietta Cavallera8Marialuisa Bocchino9Alessandro Sanduzzi Zamparelli10Francesco Ferrigno11Esterina de Carlo12Claudio de Martinis13Giovanna Fusco14COVID-19 Hospital “M. Scarlato”, Department of Pneumology, 84018 Salerno, ItalyIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, ItalyDepartment of Clinical Medicine and Surgery, Section of Respiratory Disease Federico II University Hospital, 80055 Naples, ItalyUmberto I” Hospital, Unit of Virology and Microbiology, Nocera Inferiore, 84018 Salerno, ItalyUmberto I” Hospital, Unit of Virology and Microbiology, Nocera Inferiore, 84018 Salerno, ItalyCOVID-19 Hospital “M. Scarlato”, Unit of Clinical Pathology Laboratory, 84018 Salerno, ItalyIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, ItalyIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, ItalyCOVID-19 Hospital “M. Scarlato”, Department of Radiology, 84018 Salerno, ItalyDepartment of Clinical Medicine and Surgery, Section of Respiratory Disease Federico II University Hospital, 80055 Naples, ItalyDepartment of Clinical Medicine and Surgery, Section of Respiratory Disease Federico II University Hospital, 80055 Naples, ItalyCOVID-19 Hospital “M. Scarlato”, Department of Pneumology, 84018 Salerno, ItalyIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, ItalyIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, ItalyIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, ItalyNeutralizing monoclonal antibodies (mAbs) for pre- and post-exposure prophylaxis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are largely used to prevent the progression of the disease by blocking viral attachment, host cell entry, and infectivity. Sotrovimab, like other available mAbs, has been developed against the receptor binding Domain of the <i>Spike</i> (S) glycoprotein of the virus. Nevertheless, the latest Omicron variant has shown marked mutations within the S gene, thus opening the question of the efficacy of these neutralizing molecules towards this novel variant. In the present observational study, we describe the effects of Sotrovimab in the treatment of 15 fully vaccinated patients, infected by SARS-CoV-2 Omicron sub-variants, who were selected on the basis of factors widely considered to affect a worse prognosis: immune suppression (<i>n</i> = 12) and/or chronic kidney disease (<i>n</i> = 5) with evidence of interstitial pneumonia in nine patients. The effectiveness of Sotrovimab in the treatment of severe cases of COVID-19 was demonstrated by the regression of symptoms (mean 5.7 days), no need of hospitalisation, improvement of general health conditions and viral clearance within 30 days in all patients. In conclusion, although loss or reduction of mAbs neutralizing activity against the Omicron variant have been described, Sotrovimab has clinically proven to be a safe and useful treatment for patients with high risk of progression to severe COVID-19 infected by Omicron sub-variants.https://www.mdpi.com/1999-4915/15/1/102SARS-CoV-2monoclonal antibody treatmentsotrovimabvariant of concernOmicron variantimmune suppression |
| spellingShingle | Gaetano Cicchitto Lorena Cardillo Davide Sequino Paola Sabatini Luisa Adamo Rosita Marchitiello Maurizio Viscardi Loredana Cozzolino Antonietta Cavallera Marialuisa Bocchino Alessandro Sanduzzi Zamparelli Francesco Ferrigno Esterina de Carlo Claudio de Martinis Giovanna Fusco Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series Viruses SARS-CoV-2 monoclonal antibody treatment sotrovimab variant of concern Omicron variant immune suppression |
| title | Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series |
| title_full | Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series |
| title_fullStr | Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series |
| title_full_unstemmed | Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series |
| title_short | Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series |
| title_sort | effectiveness of sotrovimab in the omicron storm time a case series |
| topic | SARS-CoV-2 monoclonal antibody treatment sotrovimab variant of concern Omicron variant immune suppression |
| url | https://www.mdpi.com/1999-4915/15/1/102 |
| work_keys_str_mv | AT gaetanocicchitto effectivenessofsotrovimabintheomicronstormtimeacaseseries AT lorenacardillo effectivenessofsotrovimabintheomicronstormtimeacaseseries AT davidesequino effectivenessofsotrovimabintheomicronstormtimeacaseseries AT paolasabatini effectivenessofsotrovimabintheomicronstormtimeacaseseries AT luisaadamo effectivenessofsotrovimabintheomicronstormtimeacaseseries AT rositamarchitiello effectivenessofsotrovimabintheomicronstormtimeacaseseries AT maurizioviscardi effectivenessofsotrovimabintheomicronstormtimeacaseseries AT loredanacozzolino effectivenessofsotrovimabintheomicronstormtimeacaseseries AT antoniettacavallera effectivenessofsotrovimabintheomicronstormtimeacaseseries AT marialuisabocchino effectivenessofsotrovimabintheomicronstormtimeacaseseries AT alessandrosanduzzizamparelli effectivenessofsotrovimabintheomicronstormtimeacaseseries AT francescoferrigno effectivenessofsotrovimabintheomicronstormtimeacaseseries AT esterinadecarlo effectivenessofsotrovimabintheomicronstormtimeacaseseries AT claudiodemartinis effectivenessofsotrovimabintheomicronstormtimeacaseseries AT giovannafusco effectivenessofsotrovimabintheomicronstormtimeacaseseries |